Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study

Romy N. Bouwmeester*, Caroline Duineveld, Kioa L. Wijnsma, Frederike J. Bemelman, Joost W. van der Heijden, Joanna A.E. van Wijk, Antonia H.M. Bouts, Jacqueline van de Wetering, Eiske Dorresteijn, Stefan P. Berger, Valentina Gracchi, Arjan D. van Zuilen, Mandy G. Keijzer-Veen, Aiko P.J. de Vries, Roos W.G. van Rooij, Flore A.P.T. Engels, Wim Altena, Renée de Wildt, Evy van Kempen, Eddy M. AdangMendy ter Avest, Rob ter Heine, Elena B. Volokhina, Lambertus P.W.J. van den Heuvel, Jack F.M. Wetzels, Nicole C.A.J. van de Kar

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
6 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology